Shots:

• The P-IIa (OpSCF-201) study evaluating safety & efficacy of OpSCF vs PBO in treating adults (n=84) with moderate to severe atopic dermatitis (AD)
• The 1EP of the study includes percent change in the Eczema Area and Severity Index (EASI) score from baseline, at week 16, while 2EPs include safety and tolerability and improvement in pruritus, body surface area, and quality of life
• In a previous phase 1a/b study involving 115 subjects, OpSCF exhibited safety and favorable tolerance during both single and multiple ascending dose administrations in healthy volunteers. OpSCF, a mAb, specifically targets the SCF248 isoform of stem cell factor, addressing the inflammatory pathway in AD

Ref: PR Newswire | Image: Opsidio

Related News:- EpimAb Biotherapeutics Entered into a License Agreement with Almirall to Develop Bispecific Antibody

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com